TY - JOUR
T1 - Prognostic biomarkers and clinical parameters in adults with atrial septal defect-related pulmonary arterial hypertension treated with sildenafil and beraprost combination therapy
AU - Ratri, Anudya Kartika
AU - Suryawan, I. Gde Rurus
AU - Ardiana, Meity
AU - Andrianto,
AU - Drakos, Stavros G.
N1 - Publisher Copyright:
© 2024 Elsevier B.V.
PY - 2024/6
Y1 - 2024/6
N2 - Background: Altered biological and environmental factors have been linked to the development of pulmonary vascular remodeling in pulmonary arterial hypertension (PAH) pathogenesis. Objectives: We determined the association between prognostic biomarkers and clinical parameters of pulmonary arterial hypertension (PAH) in adult Atrial Septal Defect (ASD) patients with right heart failure who were treated with sildenafil and beraprost combination therapy. Methods: We conducted an observational study using a cross-sectional design and examined the correlation between prognostic biomarkers (superoxide dismutase (SOD) and Platelet-derived growth factor-BB (PDGF-BB)) and clinical parameters (6 minute walking distance (6MWD) and echocardiography parameters (tricuspid annular plane systolic excursion/pulmonary artery systolic pressure (TAPSE/PASP)) in 41 adult patients with ASD diagnosed as pre-capillary pulmonary hypertension (WHO group 1) who were treated at the congenital outpatient clinic at Dr. Soetomo General Hospital Surabaya, Indonesia from October 1st to November 30th 2022. A Pearson correlation test was used to determine the correlation between normal distribution variables. Statistical analyses were done using SPSS software. Results: The results indicated a moderately negative relationship between PDGF-BB and 6MWD (Pearson, r = −0.320, p = 0.041) and a medium significantly negative relationship between PDGF-BB and TAPSE/PASP (Pearson, r = −0.347, p = 0.026). Conclusions: Lower circulating PDGF-BB is associated with better functional capacity and echocardiographic parameters in adult ASD-PAH patients receiving sildenafil and beraprost combination therapy. PDGF-BB may strongly be used as a treatment progress monitoring and prognostic biomarker.
AB - Background: Altered biological and environmental factors have been linked to the development of pulmonary vascular remodeling in pulmonary arterial hypertension (PAH) pathogenesis. Objectives: We determined the association between prognostic biomarkers and clinical parameters of pulmonary arterial hypertension (PAH) in adult Atrial Septal Defect (ASD) patients with right heart failure who were treated with sildenafil and beraprost combination therapy. Methods: We conducted an observational study using a cross-sectional design and examined the correlation between prognostic biomarkers (superoxide dismutase (SOD) and Platelet-derived growth factor-BB (PDGF-BB)) and clinical parameters (6 minute walking distance (6MWD) and echocardiography parameters (tricuspid annular plane systolic excursion/pulmonary artery systolic pressure (TAPSE/PASP)) in 41 adult patients with ASD diagnosed as pre-capillary pulmonary hypertension (WHO group 1) who were treated at the congenital outpatient clinic at Dr. Soetomo General Hospital Surabaya, Indonesia from October 1st to November 30th 2022. A Pearson correlation test was used to determine the correlation between normal distribution variables. Statistical analyses were done using SPSS software. Results: The results indicated a moderately negative relationship between PDGF-BB and 6MWD (Pearson, r = −0.320, p = 0.041) and a medium significantly negative relationship between PDGF-BB and TAPSE/PASP (Pearson, r = −0.347, p = 0.026). Conclusions: Lower circulating PDGF-BB is associated with better functional capacity and echocardiographic parameters in adult ASD-PAH patients receiving sildenafil and beraprost combination therapy. PDGF-BB may strongly be used as a treatment progress monitoring and prognostic biomarker.
KW - 6MWD
KW - Adult Atrial Septal Defect
KW - Clinical parameters
KW - PDGF-BB
KW - Prognostic biomarkers
KW - Pulmonary arterial hypertension
KW - SOD
KW - Sildenafil and beraprost combination therapy
KW - TAPSE/PASP
UR - http://www.scopus.com/inward/record.url?scp=85188828662&partnerID=8YFLogxK
U2 - 10.1016/j.ppedcard.2024.101720
DO - 10.1016/j.ppedcard.2024.101720
M3 - Article
AN - SCOPUS:85188828662
SN - 1058-9813
VL - 73
JO - Progress in Pediatric Cardiology
JF - Progress in Pediatric Cardiology
M1 - 101720
ER -